Responses
Clinical and epidemiological research
Concise report
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Compose a Response to This Article
Other responses
No responses have been published for this article.